Target intelligence / Profile preview

Phosphatidylserine (PS) on activated platelets (PS)

Target
PS
Molecular classification
Phospholipid, Lipid
01

Overview

Anionic phospholipid surfaces, predominantly phosphatidylserine (PS), are essential components of the cell-based model of coagulation (Lentz, 2003, PMID: 12837069). In quiescent platelets, PS is maintained on the inner membrane leaflet by flippases, but platelet activation triggers its translocation to the outer leaflet, a process mediated by scramblases (Zwaal et al., 2005, PMID: 15913654). This exposed anionic surface provides a high-affinity scaffold for the assembly of the tenase (factors IXa/VIIIa) and prothrombinase (factors Xa/Va) complexes, which are required for the explosive generation of thrombin (Heemskerk et al., 2013, PMID: 23303373). Because PS exposure is relatively restricted to activated platelets and damaged cells, it serves as a selective target for antithrombotic agents like Diannexin, which mask the surface to prevent clot propagation without necessarily inhibiting initial platelet adhesion (Rand et al., 2004, PMID: 15153459). Additionally, PS-targeting ligands are utilized in molecular imaging to detect thrombi and monitor cell death in various pathologies (Post et al., 2002, PMID: 12163644).

Other names
Anionic phospholipidsProcoagulant phospholipidsExposed phosphatidylserinePlatelet procoagulant surfacePhosphatidylserine
02

Mechanism of action

The primary mechanism involves the steric hindrance of coagulation factor binding. By binding with high affinity to the exposed phosphatidylserine headgroups, agents like Annexin A5 or Diannexin prevent the assembly of the tenase and prothrombinase complexes on the platelet surface, thereby halting the conversion of prothrombin to thrombin (Rand, 2000, PMID: 10807119).

03

Biological functions

Blood coagulationHemostasisCell signalingApoptosis
04

Disease associations

ThrombosisCardiovascular diseaseAntiphospholipid syndromeCancer
05

Safety considerations

Potential for systemic bleedingInterference with phagocytic clearance of apoptotic cells (efferocytosis)Immunogenicity of protein-based ligands
06

Interacting drugs

Annexin A5

4 more in the full profile.

07

Biomarkers

Annexin V bindingProcoagulant microparticle levelsThrombin generation assay

Beyond the preview

Go deeper on Phosphatidylserine (PS) on activated platelets (PS).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Phosphatidylserine (PS) on activated platelets (PS).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call